期刊文献+

定量检测bcr-abl mRNA在慢性粒细胞白血病患者异基因造血干细胞移植后的意义 被引量:6

Significance of Quantitative Detection of bcr-abl mRNA in Chronic Myeloid Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplant
下载PDF
导出
摘要 本研究确切了解CML患者异基因造血干细胞移植后bcr-abl mRNA的变化情况,为临床诊断早期复发提供实验依据。用实时荧光定量PCR方法检测15例慢性粒细胞白血病(CML)患者异基因造血干细胞移植前后78份外周血和骨髓标本的bcr-abl mRNA水平。结果表明,移植前患者的bcr-ablmRNA水平较高,中位数为29.303%;移植后1个月时检测bcr-abl mRNA水平较移植前大幅度降低,中位数为0;移植后1年内,连续多次检测bcr-abl mRNA水平,变化模式不一致,但6个月后的总体水平较6个月前明显降低,移植1年以上的受者绝大多数bcr-abl mRNA检测不到,或偶可检测到,但水平极低(0.007%、0.004%和0.021%),所检测受者的骨髓和外周血像均正常;同期骨髓与外周血bcr-abl水平无明显差异,且变化趋势一致。结论:CML患者移植后早期bcr-abl水平变化起伏较大,连续动态检测可明确其变化趋势,有助于判断移植效果、指导临床治疗,但6个月前检测到bcr-abl存在并不提示疾病复发;检测外周血bcr-abl或许更适于临床上对患者的随访。 The objective of this study was to analyze the level of bcr-abl mRNA in peripheral blood ( PB ) after allogeneic stem cell transplantation (allo-SCT) in chronic myeloid leukemia patients, providing a experimental basis for diagnosing early relapse, bcr-abl mRNA levels in 78 PB and bone marrow (BM) samples from 15 CML patients after allo- SCT were detected by using real-time quantitative PCR. The results indicated that levels of bcr-abl mRNA before transplantation were high ( median 29.303% ) and decreased greatly ( median 0) at the first month after allo-SCT. During the first year after allo-SCT, the patterns of serial bcr-abl transcripts varied in number, but the overall bcr-abl transcript levels significantly decreased at 6 months after allo-SCT. Majority of patients with undetectable or very low levels of bcr-abl mRNA were monitored after 1 year following transplantation. The hematological features of BM and PB in all detected patients remained normal. PB and BM bcr-abl values were not different significantly and had the similar trend of changes. It is concluded that the bcr-abl mRNA levels in CML patients change greatly early after allograft. Serial monitoring measurements for bcr-abl mRNA contribute to understanding the trend of change and effect of transplantation, also can be a guidance for starting therapy. But detectable levels of bcr-abl mRNA during the first 6 months do not indicate relapse. Measurements of bcr-abl mRNA of PB may be more suitable for routine monitoring long-term disease status in CML after allo-HSCT.
出处 《中国实验血液学杂志》 CAS CSCD 2007年第5期993-997,共5页 Journal of Experimental Hematology
关键词 慢性粒细胞白血病 bcr—abl融合基因 实时定量PCR 微小残留病变 chronic myelogenous leukemia bcr-abl fusion gene real-time PCR minimal residual disease
  • 相关文献

参考文献12

  • 1秦亚溱,阮国瑞,刘艳荣,李金兰,付家瑜,王卉,常艳,江滨,江倩,江浩,丘镜滢,陈珊珊,陆道培.实时定量RT-PCR监测慢性粒细胞白血病患者伊马替尼治疗过程中bcr/abl mRNA水平[J].中华血液学杂志,2005,26(1):1-5. 被引量:12
  • 2杜金伟,朱平,田丁,董作仁,杨淑莲,李松波,唐亚辉,刘辉,岑溪南,张英,朱强,祝毓琳,杨英,王东侠,王昭,崔华,马一盖,陈文明,刘复强,马键,王景文,沈悌,达万明.干扰素α-2b治疗慢性粒细胞性白血病的前瞻性随机对照研究[J].中华医学杂志,2005,85(19):1305-1309. 被引量:7
  • 3Kaeda J, O′Shea D, Szydlo RM, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplant for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood, 2006;107:4171-4176 被引量:1
  • 4秦亚溱,刘艳荣,李金兰,付家瑜,常艳,阮国瑞,王卉,丘镜滢,陆道培,陈珊珊.慢性髓性白血病异基因造血干细胞移植后M-bcr/abl及m-bcr/abl融合转录子追踪观察[J].中国实验血液学杂志,2003,11(4):368-371. 被引量:4
  • 5Stentoft J, Pallisgaard N, Kjeldsen E, et al. Kinetics of bcr-abl fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur J Haematol, 2001; 67:302-308 被引量:1
  • 6Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemia patients using “real-time” quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia, 2003;17:2474-2486 被引量:1
  • 7Gabert J, Beillard E, van-der Velden VH, et al. Standardization and quality control studies of ′real-time′ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-A Europe Against Cancer Program. Leukemia, 2003;17:2318-2357 被引量:1
  • 8马晓霞,王椿,秦尤文,颜式可,高彦荣,蔡琦.实时定量RT-PCR检测慢性粒细胞白血病bcr/abl融合基因的临床意义[J].临床血液学杂志,2005,18(3):164-168. 被引量:4
  • 9Stock W, Yu D, Karrison T,et al. Quantitative real-time RT-PCR monitoring of bcr-abl in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol, 2006; 28:1099-1103 被引量:1
  • 10Mughal TI, Yong A, Szydlo RM, et al. Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Bri J Haematol, 2001; 115:569-574 被引量:1

二级参考文献45

  • 1黄薇,曹琪,陆雁,黄秋花,王振义,陈兰,陈赛娟.用筑巢式逆转录酶/多聚酶链反应检测Ph1阳性白血病特异基因转录本[J].中华医学杂志,1994,74(11):662-665. 被引量:7
  • 2Kwok S, Higuchi R. Avoiding false positives with PCR. Nature,1989 ; 339:237 - 238. 被引量:1
  • 3Elmaagacli AH, Beelen DW, Opalka B, et al. The Risk of residual molecular and eytogenetie disease in patients with Philadelphia-chromosome positive in first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood, 1999;94:384 - 389. 被引量:1
  • 4Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implication in 346 patients. Blood, 1995 ; 85:2632 - 2638. 被引量:1
  • 5Cross NC, Hughes TP, Feng L, et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: correlations with acute graft-versusbost disease and relapse. Br J Haematol, 1993;84:67-74. 被引量:1
  • 6Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood, 1996;88:2375 -2384. 被引量:1
  • 7Saglio G, Pane F, Gottardi E, et al. Consistent amounts of acute leukemia-associated P190^BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. Blood, 1996; 87: 1075- 1080. 被引量:1
  • 8Lichty BD, Keating A, Callum J, et al. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogous leukaemia. Br J Haexnatol, 1998; 103:711 - 715. 被引量:1
  • 9Yokohama A, Karasawa M, Okamoto K, et al. ALL- and CML-type BCR/ABL mRNA transcripts in chronic myelogous leukemia and related disorders. Leuk Res, 1999; 23:477- 481. 被引量:1
  • 10Serrano J, Roman J, Sanchez J, et al. Molecular analysis of lineagespecific chimerism and minimal residual disease by RT-PCR of p210 (BCR-ABL) and P190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and P190(BCR-ABL) detection precede cytogenetic relapse. Blood, 2000;95:2659 - 2665. 被引量:1

共引文献21

同被引文献43

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部